Low-risk susceptibility alleles in 40 human breast cancer cell lines by Riaz, Muhammad et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Low-risk susceptibility alleles in 40 human breast cancer cell lines
Muhammad Riaz1, Fons Elstrodt1, Antoinette Hollestelle1, Abbas Dehghan2, 
J a nG MK l i j n 1 and Mieke Schutte*1
Address: 1Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, Rotterdam, the Netherlands and 
2Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands
Email: Muhammad Riaz - m.riaz@erasmusmc.nl; Fons Elstrodt - f.elstrodt@bioke.com; Antoinette Hollestelle - a.hollestelle@erasmusmc.nl; 
Abbas Dehghan - a.dehghan@erasmusmc.nl; Jan GM Klijn - j.g.m.klijn@erasmusmc.nl; Mieke Schutte* - a.schutte@erasmusmc.nl
* Corresponding author    
Abstract
Background: Low-risk breast cancer susceptibility alleles or SNPs confer only modest breast
cancer risks ranging from just over 1.0 to1.3 fold. Yet, they are common among most populations
and therefore are involved in the development of essentially all breast cancers. The mechanism by
which the low-risk SNPs confer breast cancer risks is currently unclear. The breast cancer
association consortium BCAC has hypothesized that the low-risk SNPs modulate expression levels
of nearby located genes.
Methods: Genotypes of five low-risk SNPs were determined for 40 human breast cancer cell lines,
by direct sequencing of PCR-amplified genomic templates. We have analyzed expression of the four
genes that are located nearby the low-risk SNPs, by using real-time RT-PCR and Human Exon
microarrays.
Results: The SNP genotypes and additional phenotypic data on the breast cancer cell lines are
presented. We did not detect any effect of the SNP genotypes on expression levels of the nearby-
located genes MAP3K1, FGFR2, TNRC9 and LSP1.
Conclusion: The SNP genotypes provide a base line for functional studies in a well-characterized
cohort of 40 human breast cancer cell lines. Our expression analyses suggest that a putative disease
mechanism through gene expression modulation is not operative in breast cancer cell lines.
Background
About ten percent of breast cancer patients have a history
of multiple breast cancer cases in their family, suggesting
the inheritance of breast cancer susceptibility alleles in
these families. Germline mutations in the BRCA1  and
BRCA2 genes are identified in about one quarter of the
families with breast cancer. Female carriers of BRCA1 and
BRCA2 mutations have an estimated 50–90% life-time
risk to develop breast cancer, classifying both genes as
high-risk susceptibility genes [1,2]. Other high-risk breast
cancer genes include the p53, PTEN and STK11 genes, but
mutations in these genes account for only few familial
breast cancers. CHEK2 was the first moderate-risk breast
cancer gene being identified [3-5]. Germline mutations in
CHEK2 are identified in up to 5% of breast cancer fami-
lies, albeit that their prevalence varies widely among pop-
ulations. Female carriers of CHEK2  mutations have a
moderate two to three fold increased risk to develop
breast cancer. By now, several other moderate-risk breast
cancer genes have been identified, including ATM, BRIP1
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and  PALB2  [6-9]. Mutations in these genes all confer
increased breast cancer risks of two to three fold and
mutations in each of these genes are identified in about
1% of the familial breast cancers. Recently, the interna-
tional breast cancer association consortium (BCAC) has
conducted a large genome-wide association study and
identified five single nucleotide polymorphisms (SNPs)
that associated with breast cancer [10]. Four of these SNPs
were within haplotype blocks that contained genes: SNP
rs2981582 locates in intron 2 of the FGFR2 gene at chro-
mosome 10q; SNP rs889312 locates near MAP3K1 at 5q;
SNP rs3803662 locates between TNRC9  and the
LOC643714 gene at 16q; and SNP rs3817198 locates
intronic in LSP1 at 11p. SNP rs13281615 locates at 8q24
in a region without any annotated genes. Importantly,
independent genome-wide association studies have asso-
ciated other SNPs in FGFR2 with breast cancer [11,12]. As
FGFR2 had already been implicated in breast cancer [13-
20], the significance of the FGFR2 SNPs as susceptibility
alleles seemed evident. The TNRC9 SNP had also been
associated with breast cancer in another study [21]. Lastly,
the 8q24 SNP was of particular interest because other
SNPs at 8q24 had been associated with increased risks of
prostate cancer and colorectal cancer [22-26]. BCAC esti-
mated that each of the five identified SNPs associated with
rather small increased breast cancer risks, ranging from
just over 1.0 to 1.3 fold, classifying them as low-risk sus-
ceptibility alleles [10]. However, these low-risk SNPs are
very common and their impact is therefore still substan-
tial, together accounting for almost 5% of the familial
breast cancers.
The mechanism by which the low-risk susceptibility alle-
les confer breast cancer risks was obscure [10]. In analogy
with the high-risk and moderate-risk breast cancer genes,
it had been anticipated that the identified SNPs associated
with disease-causing alleles in the coding sequences of
nearby located genes. However, extensive sequencing
efforts have not identified such alleles in the SNP-associ-
ated haplotype blocks, suggesting that the SNPs them-
selves might be the disease-causing susceptibility alleles
[10]. BCAC therefore proposed an alternative disease
mechanism that involves expression modulation of genes
located in the vicinity of the identified SNPs, thereby con-
ferring low breast cancer risks. Here, we have evaluated
expression modulation in a well-characterized cohort of
40 human breast cancer cell lines, allowing us to specifi-
cally address whether this mechanism might operate in
breast cancer cells.
Methods
Breast cancer cell lines
The 40 human breast cancer cell lines used in this study
are listed in Table 1 and have been described in detail else-
where [27]. Microsatellite analysis with nearly 150 poly-
morphic markers had shown that all cell lines are unique
and monoclonal [28].
Genotyping
Genotypes of five low-risk susceptibility alleles have been
determined: rs889312 (A>C) near the MAP3K1  gene;
rs2981582 (C>T) in the FGFR2 gene; rs3803662 (C>T)
near the TNRC9 gene; rs3817198 (T>C) in the LSP1 gene
and rs13281615 (A>G) that located in a gene desert at
chromosome 8q24 [10]. Genotyping was performed by
direct sequencing of PCR-amplified genomic templates,
using the BigDye Terminator V3.1 Cycle Sequencing Kit
(Applied Biosystems) and an ABI 3130xL Genetic Ana-
lyzer. Primer sequences are available upon request.
Allele frequencies of cases and controls reported by BCAC
have been obtained by using their reported Odds Ratio
data [10], and inferring allele frequencies by assuming
that Odds Ratios reflect the ratio of minor allele carriers
versus major allele carriers from the cases divided by the
ratio of minor allele carriers versus major allele carriers
from the controls.
Expression analysis
Transcript expression levels of four genes have been deter-
mined: MAP3K1, FGFR2, TNRC9 and LSP1. Quantitative
real-time PCR (qPCR) was performed on cDNA templates
that had been generated with oligo-dT and random hex-
amer primers from total RNA isolates, using Power SYBR
Green PCR Master Mix (Applied Biosystems) and an ABI
Prism 7700. Ct values were normalized according HPRT
and HMBS housekeeper Ct values. Transcript expression
had also been determined by Human Exon 1.0 ST micro-
arrays (Affymetrix), as described elsewhere [29]. The exon
array data have been deposited in NCBI's Gene Expression
Omnibus [30] and are accessible through GEO Series
accession number GSE16732.
Statistical analysis
Statistical analyses were performed with Statistical Pack-
age for the Social Sciences (SPSS) version 11.5, consider-
ing P-values of less than 0.05 significant. Fisher's exact test
was used to determine association of the SNP genotypes
with the breast cancer cell lines. The Kruskal Wallis test
was used to compare gene expression levels among three
SNP genotype groups (major homozygotes, heterozy-
gotes, and minor homozygotes).
Results and discussion
Genotyping of low-risk susceptibility alleles in breast 
cancer cell lines
Genotypes of five low-risk susceptibility alleles [10] were
determined in a cohort of 40 human breast cancer cell
lines. For each SNP, frequencies of major homozygotes,
heterozygotes and minor homozygotes are shown in Fig-BMC Cancer 2009, 9:236 http://www.biomedcentral.com/1471-2407/9/236
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ure 1a and genotypes are detailed in Table 1. Frequencies
of homozygote genotypes typically were higher than
anticipated, likely related to allelic losses in the cell line
samples (Figure 1a; [10]). For four SNPs (8q24, MAP3K1,
FGFR2 and TNRC9), the minor allele frequencies among
the cell lines were higher than among the 21,860 BCAC
breast cancer cases and 22,578 population controls (Fig-
ure 1b; [10]). Fisher's exact testing indicated that the
minor allele frequencies among the cell lines were signifi-
cantly higher than the BCAC population controls for two
SNPs: MAP3K1 and TNRC9 (Figure 1b). In Table 1 and 2,
we also included previously-determined phenotypic and
Table 1: Genotypes of five low-risk SNPs in 40 human breast cancer cell lines
Breast cancer cell lines SNP genotypes and allelic losses
8q24 Loss 8q MAP3K1 Loss 5q FGFR2 Loss 10q TNRC9 Loss 16q LSP1 Loss 11p
SUM185PE Het No Het No Maj H nd Min H nd Maj H nd
BT483 Het No Maj H No Min H Yes Maj H No Maj H No
MDA-MB-134VI Het No Het No Het No Het No Maj H No
MDA-MB-175VII Het No Min H No Het No Het No Maj H No
MDA-MB-415 Het No Het No Min H Yes Het No Het No
MPE600 Het No Maj H nd Het No Maj H nd Het No
SUM52PE Maj H nd Maj H nd Maj H nd Maj H nd Maj H nd
CAMA-1 Het No Het No Min H No Maj H Yes Maj H Yes
MCF-7 Maj H No Het No Maj H No Het No Maj H Yes
ZR75-1 Het No Het No Min H Yes Maj H Yes Het No
SUM44PE Het No Min H nd Maj H nd Het No Min H nd
T47D Het No Het No Maj H No Min H Yes Min H Yes
MDA-MB-361 Het No Het No Maj H No Het No Min H No
BT474 Het No Maj H No Maj H Yes Maj H No Maj H No
UACC812 Min H No Min H No Het No Het No Min H Yes
ZR75-30 Maj H nd Min H nd Min H nd Min H nd Maj H nd
OCUB-F Maj H nd Maj H nd Min H nd Min H nd Maj H nd
SK-BR-5 Het No Maj H nd Min H nd Min H nd Maj H nd
SUM190PT Min H nd Min H nd Maj H nd Min H nd Maj H nd
SUM225CWN Het No Maj H nd Maj H nd Maj H nd Het No
MDA-MB-330 Het No Min H Yes Min H Yes Het No Maj H No
MDA-MB-453 Het No Het No Min H Yes Maj H Yes Maj H Yes
SK-BR-3 Min H Yes Het No Het No Maj H Yes Min H No
EVSA-T Min H nd Min H nd Maj H nd Maj H nd Min H nd
UACC893 Maj H No Maj H No Maj H Yes Het No Maj H No
BT20 Min H No Maj H Yes Maj H Yes Maj H Yes Het No
HCC1937 Het No Min H nd Het No Het No Maj H nd
MDA-MB-468 Maj H Yes Maj H Yes Maj H Yes Maj H Yes Maj H Yes
SUM149PT Min H nd Het No Min H nd Min H nd Maj H Yes
SUM229PE Maj H nd Maj H nd Maj H nd Maj H nd Min H nd
BT549 Maj H No Maj H No Maj H Yes Het No Min H Yes
Hs578T Het No Maj H Yes Min H Yes Min H No Maj H No
MDA-MB-157 Maj H No Maj H Yes Maj H Yes Min H No Maj H Yes
MDA-MB-231 Maj H Yes Het No Het No Maj H Yes Het No
MDA-MB-436 Maj H Yes Maj H Yes Maj H No Min H No Maj H Yes
SK-BR-7 Het No Het No Min H nd Maj H nd Het No
SUM159PT Maj H nd Het No Min H nd Het No Maj H nd
SUM1315MO2 Het No Maj H nd Min H nd Het No Maj H nd
SUM102PT Het No Het No Maj H nd Het No Maj H nd
MDA-MB-435s Maj H No Maj H Yes Maj H Yes Maj H Yes Maj H No
Total major homozygotes 13 17 19 16 25
Total heterozygotes 21 15 7 14 7
Total minor homozygotes 6 8 14 10 8
Percentage of allelic loss 13 25 52 32 37
Genotypes of five low-risk SNPs have been determined in the current study. Allelotype data have been reported elsewhere and involved 
microsatellite analysis. Loss: Yes, allelic loss at the indicated chromosomal region; and No, no allelic loss at the indicated chromosomal region. nd, 
not determined; Maj H, major homozygotes; Min H, minor homozygotes; Het, heterozygote allele carriers.BMC Cancer 2009, 9:236 http://www.biomedcentral.com/1471-2407/9/236
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Genotypes and minor allele frequencies of five low-risk breast cancer susceptibility alleles or SNPs in human breast cancer cell  lines Figure 1
Genotypes and minor allele frequencies of five low-risk breast cancer susceptibility alleles or SNPs in human 
breast cancer cell lines. 1a. Gray bars represent SNP genotype frequencies of 21,860 blood-derived samples from breast 
cancer cases reported by the breast cancer association consortium BCAC [10], and white bars represent genotype frequencies 
in 40 breast cancer cell lines. Maj H, major homozygotes; Min H, minor homozygotes; and Het, heterozygote allele carriers. 
The major and minor alleles of each allele are indicated between brackets. 1b. Black and gray bars represent minor allele fre-
quencies in 22,578 population controls and 21,860 breast cancer cases, respectively, as reported by BCAC [10]. White bars 
represent frequencies identified in 40 breast cancer cell lines.BMC Cancer 2009, 9:236 http://www.biomedcentral.com/1471-2407/9/236
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genotypic data on the breast cancer cell lines, including
data on molecular subtyping and allelotyping (Hollestelle
et al. submitted for publication; [28]). Together with the
SNP genotypes, we provide a base line for functional stud-
ies in this cohort of breast cancer cell lines.
Expression levels of nearby located genes in breast cancer 
cell lines do not correlate with their SNP genotype
Surprisingly, BCAC had not identified disease-causing
gene variants within the haplotype blocks of the five low-
risk SNPs [10]. They proposed an alternative disease
mechanism, in which SNP genotypes modulate expres-
sion levels of nearby located genes. Such disease mecha-
nism was conceivable because the minor SNP alleles
confer only low risks for breast cancer. Here, we have eval-
uated whether gene expression modulation is operative in
breast cancer cell lines, by associating SNP genotypes of
the breast cancer cell lines with the expression levels of
nearby located genes.
Table 2: Molecular and phenotypic characterizations of 40 breast cancer cell lines
Breast cancer cell lines Breast cancer subtype Intrinsic subtype Protein expression
ER PgR ERBB2 3-neg
SUM185PE Luminal-type Luminal - - - +
BT483 Luminal-type Luminal + - + -
MDA-MB-134VI Luminal-type Luminal + - - -
MDA-MB-175VII Luminal-type Luminal + - - -
MDA-MB-415 Luminal-type Luminal + - - -
MPE600 Luminal-type Luminal + - + -
SUM52PE Lumina-type Luminal + - + -
CAMA-1 Lumina-type Luminal + + + -
MCF-7 Luminal-type Luminal + + - -
ZR75-1 Luminal-type Luminal + + + -
SUM44PE Luminal-type Luminal + + - -
T47D Luminal-type Luminal + + - -
MDA-MB-361 Luminal-type Luminal + + ++ -
BT474 Luminal-type Luminal - + ++ -
UACC812 Luminal-type Luminal - + ++ -
ZR75-30 Luminal-type Luminal + - ++ -
OCUB-F Luminal-type Luminal - - ++ -
SK-BR-5 Luminal-type Luminal - - ++ -
SUM190PT Luminal-type nd - - ++ -
SUM225CWN Luminal-type nd - - ++ -
MDA-MB-330 Luminal-type ERBB2 + - ++ -
MDA-MB-453 Luminal-type ERBB2 - - ++ -
SK-BR-3 Luminal-type ERBB2 - - ++ -
EVSA-T Luminal-type ERBB2 - - ++ -
UACC893 Luminal-type ERBB2 - - ++ -
BT20 Basal-type Basal-like - - - +
HCC1937 Basal-type Basal-like - - - +
MDA-MB-468 Basal-type Basal-like - - - +
SUM149PT Basal-type Basal-like - - - +
SUM229PE Basal-type Basal-like - - - +
BT549 Basal-type Normal-like - - - +
Hs578T Basal-type Normal-like - - - +
MDA-MB-157 Basal-type Normal-like - - - +
MDA-MB-231 Basal-type Normal-like - - - +
MDA-MB-436 Basal-type Normal-like - - - +
SK-BR-7 Basal-type Normal-like - - - +
SUM159PT Basal-type Normal-like - - - +
SUM1315MO2 Basal-type Normal-like - - - +
SUM102PT Basal-type Normal-like nd nd nd nd
MDA-MB-435s Basal-type Normal-like - - - +
Total phenotype positives 14 8 13 16
Phenotypic characterizations have been reported elsewhere and involved protein expression patterns of the cell lines for the breast cancer 
subtyping (cytokeratins, ER, PgR and ERBB2) and expression of the intrinsic gene set for the intrinsic subtyping (Hollestelle et al. submitted for 
publication). Protein expression: +, expressed; ++, over expressed; and -, not detectable; 3-neg, triple-negative.BMC Cancer 2009, 9:236 http://www.biomedcentral.com/1471-2407/9/236
Page 6 of 10
(page number not for citation purposes)
Gene expression data of the four genes physically nearest
to the SNPs were obtained by Affymetrix Human Exon 1.0
ST microarray profiling and by qPCR analysis. Both tran-
script expression analysis methods revealed similar
expression levels for each of the four genes: MAP3K1,
FGFR2,  TNRC9  and  LSP1, with Spearman correlation
coefficients of -0.6, -0.7, -0.8 and -0.4, respectively,
among the 40 breast cancer cell lines (Table 3 and Figures
2 and 3). Because BCAC had shown that the low-risk SNPs
confer breast cancer risks in a dose-dependent manner,
with the highest risks for the minor homozygotes [10],
association between gene expression levels and SNP gen-
otypes was performed by three-group comparisons. Exon
array data are shown in Figure 2, with cell lines from each
genotype group depicted in a different color. Unique out-
liers typically represented decreased expression of one or
more probes sets, such as exon 17 of MAP3K1 or exons 3–
5 of TNRC9, possibly related to the presence of SNPs in
probe sequences, alternative splicing or genomic dele-
tions [29]. Expression of recurrent isoforms as reported by
NCBI was detected only for the FGFR2 gene, with two cell
lines expressing the isoform that lacked exon 9. Both cell
lines were minor homozygotes for the FGFR2 SNP. Over-
all, there was no apparent association between the exon
array expression level of each of the four genes and their
SNP genotypes (Figure 2). The qPCR Ct-values are
detailed in Table 3 and the three-group comparisons are
shown in Figure 3. Again, we did not detect any associa-
Normalized expression levels from Affymetrix Human Exon 1.0 ST microarrays of 2a. MAP3K1; 2b. FGFR2; 2c. TNRC9; and 2d  LSP1; from 40 human breast cancer cell lines Figure 2
Normalized expression levels from Affymetrix Human Exon 1.0 ST microarrays of 2a. MAP3K1; 2b. FGFR2; 2c. 
TNRC9; and 2d. LSP1; from 40 human breast cancer cell lines. Kruskal Wallis testing using the average expression 
among all probe sets for each gene did not reveal significant associations between gene expression and SNP genotypes. Each 
line represents a cell line, with the color-coding according the genotype groups: green, major homozygotes; red, minor 
homozygotes; and blue, heterozygotes. Two cell lines with the delEx9 isoform of FGFR2 are indicated with bold red lines. 
Probe sets for each gene were ordered by physical location and indicated by exon, where probe sets that were not unique for 
that gene were omitted. Probe sets with expression values less than the background of 50 were also omitted, unless more than 
3 cell lines had expression levels higher than 100.BMC Cancer 2009, 9:236 http://www.biomedcentral.com/1471-2407/9/236
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Correlation of gene expression levels of 3a. MAP3K1; 3b. FGFR2; 3c TNRC9; and 3d. LSP1; with the SNP genotypes in 40 human  breast cancer cell lines Figure 3
Correlation of gene expression levels of 3a. MAP3K1; 3b. FGFR2; 3c. TNRC9; and 3d. LSP1; with the SNP geno-
types in 40 human breast cancer cell lines. Kruskal Wallis testing did not reveal any significant association between gene 
expression and SNP genotypes. Maj H, major homozygotes; Min H, minor homozygotes; and Het, heterozygote allele carriers. 
The number of cell lines in each genotype group is indicated under the genotypes and data are detailed in Table 1.BMC Cancer 2009, 9:236 http://www.biomedcentral.com/1471-2407/9/236
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tion between gene expression levels with SNP genotypes
for the four genes. It is possible that gene expression levels
are affected by allelic loss of the gene loci. We therefore
also have compared gene expression levels in major and
minor homozygotes with allelic loss to the gene expres-
sion levels in cell lines without allelic loss, but gene
expression levels did not correlate with allelic losses either
(Table 4). Altogether, these results strongly suggest that a
putative disease mechanism by expression modulation
does not operate via cancer cells. Yet, recent studies have
shown that expression levels of the FGFR2, MAP3K1 and
TNRC9 genes associated with their SNP genotype in clini-
cal breast cancer samples [31,32]. It may be that expres-
sion modulation is operative in non-neoplastic stromal or
epithelial cells and perhaps only early in carcinogenesis.
Alternatively, it may be that expression modulation of
Table 3: Gene expression analysis of MAP3K1, FGFR2, TNRC9 and LSP1 in 40 human breast cancer cell lines by quantitative RT-PCR, 
represented by normalized Ct values
Breast cancer cell lines Transcript expression (normalized Ct values)
MAP3K1 FGFR2 TNRC9 LSP1
BT20 23 30 45 38
BT474 24 35 22 35
BT483 22 31 25 36
BT549 29 32 39 40
CAMA-1 24 33 26 45
EVSA-T 25 33 25 45
HCC1937 26 32 37 45
Hs578T 26 45 45 34
MCF-7 25 34 28 39
MDA-MB-134VI 22 37 24 35
MDA-MB-157 25 44 33 29
MDA-MB-175VII 24 35 23 36
MDA-MB-231 26 45 45 35
MDA-MB-330 26 32 27 33
MDA-MB-361 23 34 23 44
MDA-MB-415 23 28 20 33
MDA-MB-435s 25 45 45 45
MDA-MB-436 26 35 31 37
MDA-MB-453 24 36 29 45
MDA-MB-468 25 35 37 37
MPE600 23 31 22 42
OCUB-F 23 39 23 42
SK-BR-3 25 32 26 37
SK-BR-5 23 37 21 43
SK-BR-7 26 39 45 35
SUM102PT 25 35 32 29
SUM1315M02 26 43 44 35
SUM149PT 27 38 45 37
SUM159PT 27 45 43 34
SUM185PE 23 38 23 45
SUM190PT 24 45 23 45
SUM225CWN 24 36 23 39
SUM229PE 25 39 33 36
SUM44PE 22 41 26 36
SUM52PE 24 24 24 37
T47D 20 36 45 35
UACC812 24 38 24 45
UACC893 21 36 25 36
ZR75-1 24 36 24 32
ZR75-30 23 33 23 43
Total high expressers (Ct <20) 1 0 1 0
Total moderate expressers (Ct 20–30) 39 2 23 2
Total low expressers (Ct >30–35) 0 12 4 5
Total no expressers (Ct >35) 0 26 12 33BMC Cancer 2009, 9:236 http://www.biomedcentral.com/1471-2407/9/236
Page 9 of 10
(page number not for citation purposes)
these genes was operative in invasive breast cancer cells
but was lost upon in vitro propagation of the cell lines.
Expression analysis of carefully dissected tumor cells and
non-neoplastic epithelial and stromal cells from clinical
breast cancer samples should resolve this issue and may
determine the precise mechanism of expression modula-
tion by low-risk breast cancer susceptibility alleles.
Conclusion
We present the genotypes of five low-risk susceptibility
alleles or SNPs of 40 human breast cancer cell lines. Using
this cell line model, we have evaluated the BCAC hypoth-
esis that low-risk SNPs confer breast cancer risks by mod-
ulation of expression levels of nearby located genes. We
found no evidence for expression modulation in the
breast cancer cell lines, suggesting that such disease mech-
anism is more likely to operate in non-neoplastic epithe-
lial or stromal cells or has been lost during in vitro
propagation of the cell lines.
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